Binds An Enzyme Patents (Class 435/338)
-
Publication number: 20120135004Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).Type: ApplicationFiled: August 26, 2011Publication date: May 31, 2012Applicant: Gilead Biologics, Inc.Inventors: Scott McCauley, Maria Vaysberg
-
Publication number: 20120082680Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Ayesha Sitlani, Carl P. Sparrow, Shilpa Pandit, Jon H. Condra, Dana D. Wood, Timothy S. Fisher
-
Publication number: 20120082679Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120077964Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 27, 2011Publication date: March 29, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120076799Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120064542Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of AAD-1 (aryloxyalkanoate dioxygenase) enzyme. These monoclonal antibodies are surprisingly well suited for detecting AAD-1 transgenic event gene products in a variety of plants and plant tissues. The invention further provides quantitative and qualitative immunoassays using the immunoglobulins of the invention.Type: ApplicationFiled: August 26, 2011Publication date: March 15, 2012Applicant: DOW AGROSCIENCES LLCInventors: Shawna K. EMBREY, Gaofeng LIN, Guomin SHAN
-
Patent number: 8124352Abstract: Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.Type: GrantFiled: June 20, 2007Date of Patent: February 28, 2012Assignee: Genentech, Inc.Inventors: Daniel K. Kirchhofer, Rajesh Vij
-
Publication number: 20120015435Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.Type: ApplicationFiled: September 2, 2011Publication date: January 19, 2012Inventors: Hong Liang, Yasmina Noubia Abdiche, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Julie Jia Li Hawkins, Jaume Pons, Yuli Wang
-
Publication number: 20110318362Abstract: The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell.Type: ApplicationFiled: August 8, 2011Publication date: December 29, 2011Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventor: John C. Reed
-
Publication number: 20110300556Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of an aryloxyalkanoate dioxygenase enzyme.Type: ApplicationFiled: June 2, 2011Publication date: December 8, 2011Applicant: DOW AGROSCIENCES LLC.Inventors: Guomin Shan, Gaofeng Lin, Joelene K. Smith Drake, Marcelo Sosa
-
Publication number: 20110296544Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: May 16, 2011Publication date: December 1, 2011Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Alqun Li, Tao He, Ian McCaffery
-
Publication number: 20110268744Abstract: The present invention provides isolated M. tuberculosis protein that is a putative Ketol-acid reductoisomerase (KARI; SEQ ID NO: 1) and immunogenic peptide fragments thereof, and antibodies produced against the full-length protein and immunogenic peptide fragments for the diagnosis of tuberculosis and/or infection by one or more mycobacteria of the M. tuberculosis complex in humans, for example using an antigen-based sandwich ELISA format. The present invention also provides multianalyte assays in which the KARI-based diagnostic assays of the present invention are multiplexed with the detection of one or more immunogenic epitopes from one or more other proteins of said mycobacteria e.g., anyone of SEQ IDS NOs: 2, 14, 21, 28-29, 36, or 44, including any combinations thereof.Type: ApplicationFiled: May 26, 2009Publication date: November 3, 2011Inventors: Ian Garthwaite, Robyn Lindner, Susanne Pedersen
-
Publication number: 20110262452Abstract: The invention provides hepsin antibodies, and compositions comprising and methods of using these antibodies.Type: ApplicationFiled: October 21, 2010Publication date: October 27, 2011Applicant: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer, Paul M. Moran, Yingnan Zhang
-
Publication number: 20110091477Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.Type: ApplicationFiled: October 18, 2010Publication date: April 21, 2011Applicant: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer
-
Publication number: 20110076705Abstract: Disclosed are antibodies and methods for detecting pregnancy in an animal. In certain aspects antibodies used binds immunologically to at least two PAGs selected from PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 and PAG21. Antibody encoding nucleic acids are also provided, as are kits, methods of use and additional antibody related compositions.Type: ApplicationFiled: December 12, 2008Publication date: March 31, 2011Applicants: MONSANTO TECHNOLOGY LLC, THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Nagappan Mathialagan, Roberts M. Robert, Michael F. McGrath, Jonathan Green
-
Patent number: 7906297Abstract: The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.Type: GrantFiled: July 17, 2006Date of Patent: March 15, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Mark Livingstone, Hong Ruan, Robert Polakiewicz
-
Publication number: 20100330092Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: ApplicationFiled: July 8, 2008Publication date: December 30, 2010Applicant: SHIONLGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
Patent number: 7858329Abstract: The invention relates to a method for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not comprising determining the level of histone acetylation in the sample by use of an antibody capable of binding to acetylated histone, and classifying the disorder as to be treated with an HDAC inhibitor when the level of histone acetylation is significantly lower than that of a reference sample. The invention further relates to the diagnostic and prognostic use of specific antibodies and cell lines producing them.Type: GrantFiled: September 30, 2003Date of Patent: December 28, 2010Assignee: TopoTarget Germany AGInventors: Giuseppe Pier Pelicci, Saverio Minucci, Daniele Piccini, Marco Maccarana, Simona Ronzoni, Beatriz Liliana Areces, Mario Faretta -
Publication number: 20100317835Abstract: A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin ?v?3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin ?v?1-dependent cell adhesion, and so on.Type: ApplicationFiled: February 12, 2009Publication date: December 16, 2010Inventors: Toshimitsu Uede, Yutaka Matsui
-
Patent number: 7846673Abstract: Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer.Type: GrantFiled: August 19, 2004Date of Patent: December 7, 2010Assignee: Institute of Virology of the Slovak Academy of SciencesInventors: Jaromir Pastorek, Silvia Pastorekova, Miriam Zatovicova, Jan Zavada, Marta Ortova Gut, Zuzanna Zavadova
-
Publication number: 20100303828Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.Type: ApplicationFiled: January 30, 2009Publication date: December 2, 2010Applicant: INSERM Institut National de la Sante et de la Recherche Medicale)Inventors: Yves Levy, Jean-Francois Eliaou, Armand Bensussan, Nathalie Bonnefoy-Berard
-
Patent number: 7829095Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.Type: GrantFiled: February 7, 2003Date of Patent: November 9, 2010Assignee: CSL Behring GmbHInventors: Juergen Roemisch, Wiegand Lang, Annette Feussner, Gudrun Muth-Naumann, Hans-Arnold Stoehr, Christian Kannemaier, Klaus Preissner, Fumie Nakazawa
-
Patent number: 7820797Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: GrantFiled: July 3, 2008Date of Patent: October 26, 2010Assignee: University of Georgia Research Foundation, Inc.Inventor: Geert-Jan Boons
-
Patent number: 7803565Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.Type: GrantFiled: April 5, 2006Date of Patent: September 28, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Frucht, Hui Fang
-
Publication number: 20100226929Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.Type: ApplicationFiled: April 27, 2009Publication date: September 9, 2010Applicant: University of Iowa Research FoundationInventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, JR., Jeffrey Robert Erickson
-
Patent number: 7771960Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: GrantFiled: October 15, 2008Date of Patent: August 10, 2010Assignee: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis, Barbara O'Brien, Marilyn Strong-Townsend
-
Patent number: 7722875Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding canine pancreatic lipase polypeptides, allelic variants and fragments thereof. Vectors and host cells containing the polynucleotide sequences and methods for expressing the polypeptides. Monoclonal antibodies that specifically binds to the canine pancreatic lipase polypeptides. Cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of canine pancreatic lipase in a biological sample. The methods include using the monoclonal antibodies to specifically bind to canine pancreatic lipase polypeptides. The method includes using standards of recombinant canine pancreatic lipase. Devices and kits for performing methods for detecting canine pancreatic lipase in biological samples.Type: GrantFiled: July 13, 2007Date of Patent: May 25, 2010Assignee: IDEXX Laboratories, Inc.Inventors: Melissa Beall, Stacey Pazar Huth, Eugene Regis Krah
-
Publication number: 20100034826Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: ApplicationFiled: December 8, 2006Publication date: February 11, 2010Applicant: MEDAREX, INCInventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
-
Patent number: 7632498Abstract: Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.Type: GrantFiled: August 9, 2006Date of Patent: December 15, 2009Assignee: TriPath Imaging, Inc.Inventors: Douglas P. Malinowski, Timothy J. Fischer, Adriann J. Taylor
-
Patent number: 7611855Abstract: Using two types of antibodies, i.e., a first antibody having a higher affinity for a target substance than for a competitive substance and a second antibody having a higher affinity for the competitive substance than for the target substance, a specimen is treated with these two antibodies. Then, the competitive substance in the specimen first binds to the second antibody and thus the ratio of the target substance to the competitive substance in the specimen is enlarged. As a result, the target substance becomes liable to bind to the first antibody and, in its turn, the reactivity of the target substance is elevated compared with the case of using the first antibody alone. Thus, the target substance in the specimen can be accurately assayed while avoiding the effects of the competitive substance contained in the specimen.Type: GrantFiled: December 24, 2003Date of Patent: November 3, 2009Assignee: Nitto Boseki Co., Ltd.Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Fumio Nomura, Takeshi Tomonaga, Katsuhiro Katayama
-
Patent number: 7579447Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.Type: GrantFiled: March 7, 2006Date of Patent: August 25, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
-
Publication number: 20090202526Abstract: The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.Type: ApplicationFiled: December 23, 2004Publication date: August 13, 2009Inventor: Jaume Pons
-
Patent number: 7572444Abstract: Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.Type: GrantFiled: December 16, 2005Date of Patent: August 11, 2009Assignees: Amgen Fremont Inc., Dendreon CorporationInventors: Ian Foltz, Chadwick King, Peter Koon Bong Ling, Jaspal Singh Kang, Kathy Manchulenko, Francine Chen, Caroline Darne Scatena, Bruce A. Keyt, Edwin Madison, Wayne R. Godfrey, Stanislaw K. Morkowski, Jennifer H. Richardson
-
Publication number: 20090148866Abstract: The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample.Type: ApplicationFiled: May 16, 2008Publication date: June 11, 2009Applicant: Abbott LaboratoriesInventors: Saul A. Datwyler, David J. Hawksworth, Stephen C. Hsu, Matthew S. Matias, David P. Pacenti, Mary S. Pinkus, Jessie W. Shih, Bryan C. Tieman, Joan D. Tyner, Robert N. Ziemann, Lowell J. Tyner
-
Publication number: 20090142776Abstract: The subject of the present invention is to provide a useful antibody for measuring ADAMTS13 activity, in particular, a monoclonal antibody and a method for measuring ADAMTS13 activity. Further, another subject of the present invention also is to provide a monoclonal antibody which has specific reactivity to an antigenic determinant site produced by reacting ADAMTS13 with VWF that is a substrate or a partial peptide of VWF that is a potential substrate, but has no specific reactivity to the complete VWF molecule, and a use of the antibody of interest. Those subjects were achieved by succeeding in obtaining a monoclonal antibody (anti-N-10 monoclonal antibody) which has specific reactivity to a cleavage site that is cleavable by ADAMTS13 in the partial peptide of VWF, and further by finding a method for measuring ADAMTS13 activity using the monoclonal antibody of interest.Type: ApplicationFiled: January 26, 2006Publication date: June 4, 2009Inventors: Seiji Kato, Hisahide Hiura, Yoshihiro Fujimura, Masanori Matsumoto
-
Patent number: 7524939Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.Type: GrantFiled: July 9, 2003Date of Patent: April 28, 2009Assignee: United States of America as represented by Department of Health and Human ServicesInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Publication number: 20090098576Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: ApplicationFiled: October 15, 2008Publication date: April 16, 2009Applicant: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis Krah, Barbara O'Brien, Marilyn Strong-Townsend
-
Patent number: 7432044Abstract: The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin.Type: GrantFiled: July 25, 2005Date of Patent: October 7, 2008Assignee: Genentech, Inc.Inventors: Daniel K. Kirchhofer, Paul M. Moran, Mark D. Peek
-
Patent number: 7407743Abstract: The present invention relates to a method for measuring a ceruloplasmin concentration, and more particularly, to a method for measuring a ceruloplasmin in a blood spot based on a standard concentration curve obtained through an enzyme-linked immunosorbent assay (ELISA) or a dissociation-enhanced time-resolved fluoroimmunoassay using a ceruloplasmin-specific polyclonal antibody or a ceruloplasmin-specific monoclonal antibody.Type: GrantFiled: September 7, 2004Date of Patent: August 5, 2008Assignee: Zenovac, Inc (KR)Inventors: Si Houn Hahn, Young-Ju Jang, Soo-Young Lee, Ha-Cheol Shin, Sun-Young Park, Eun-Sun Yu, Hee-Sung Han
-
Patent number: 7309779Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: June 2, 2006Date of Patent: December 18, 2007Assignee: Bristol-Myers Squibb CompanyInventors: John N. Feder, Shujian Wu, Thomas C. Nelson, Liana M. Lee
-
Patent number: 7273610Abstract: Proteins that bind to ET2, such as immunoglobulins that inhibit ET2 with high affinity and selectivity, are provided. The ET2 binding proteins can be used to treat a variety of disorders, including angiogenesis-associated disorders.Type: GrantFiled: August 12, 2004Date of Patent: September 25, 2007Assignee: Dyax Corp.Inventors: Andrew Nixon, Edwin L. Madison
-
Publication number: 20070190062Abstract: Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.Type: ApplicationFiled: August 9, 2006Publication date: August 16, 2007Applicant: TriPath Imaging, Inc.Inventors: Douglas P. Malinowski, Timothy J. Fischer, Adriann J. Taylor
-
Patent number: 7195926Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.Type: GrantFiled: March 8, 2000Date of Patent: March 27, 2007Assignee: Incyte CorporationInventors: Roger Coleman, Scott Michael Braxton, Jeffrey J. Seilhamer
-
Patent number: 7176291Abstract: The present invention provides two unique monoclonal antibodies directed against a portion of the human Glycine N-methyltransferase, and methods of use for the monoclonal antibodies in detecting, monitoring and diagnosing malignancies characterized by down-regulation of expression or inappropriate expression of the Glycine N-methyltransferase.Type: GrantFiled: November 22, 2002Date of Patent: February 13, 2007Assignee: Gene Research Lab. Co., Ltd.Inventor: Yi-Ming A. Chen
-
Patent number: 7105330Abstract: The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods. The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind native hpHAse (anti-native hpHAse antibodies), and anti-native hpHAse antibodies identified by this screening method. The invention also features an assay for sensitive detection of HAse activity using biotinylated hyaluronic acid (bHA). Purification and characterization of hpHAse lead to the inventors' additional discovery that hpHAse is encoded by the LuCa-1 gene, which gene is present in the human chromosome at 3p21.3, a region associated with tumor suppression. The invention additionally features methods of treating tumor-bearing patients by administration of hpHAse and/or transformation of cells with hpHAse-encoding DNA.Type: GrantFiled: July 18, 2003Date of Patent: September 12, 2006Assignee: The Regents of the University of CaliforniaInventors: Robert Stern, Gregory I. Frost, Anthony Csoka, Tim M. Wong
-
Patent number: 7105311Abstract: The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample.Type: GrantFiled: May 3, 2002Date of Patent: September 12, 2006Assignee: Immunetics, Inc.Inventor: Victor Kovalenko
-
Patent number: 7074903Abstract: Monocolonal antibodies having a higher reactivity with tartrate-resistant acid phosphatase 5b (TRACP 5b) than tartrate-resistant acid phosphatase 5a (TRACP 5a) and having a higher specificity to TRACP 5b can be obtained by cell fusion using as antigens TRACP 5b purified from human osteoclasts. By using the monoclonal antibody, TRACP 5b in a sample can be detected specifically with a high sensitivity.Type: GrantFiled: April 29, 2003Date of Patent: July 11, 2006Assignee: Nitto Boseki Co., Ltd.Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Kumiko Sasagawa, Katsuhiro Katayama
-
Patent number: 7015008Abstract: The present invention features antibodies referred to herein as “MAb50-4” and “MAb184-10”, and polypeptides that compete with MAb50-4 and MAb184-10 for binding to CYP2D6. MAb50-4 can be produced by ATCC No. PTA-3489, while MAb184-10 can be produced by ATCC No. PTA-1999.Type: GrantFiled: September 25, 2001Date of Patent: March 21, 2006Assignee: Merck & Co., Inc.Inventors: Magang Shou, Qin Mei
-
Patent number: 6893870Abstract: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.Type: GrantFiled: July 29, 2003Date of Patent: May 17, 2005Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben, Y. Eric Shi
-
Patent number: 6893831Abstract: The present invention provides an immunoassay for specifically measuring with high sensitivity PIVKA-II in serum or plasma through antigen-antibody reaction by adding an animal serum containing thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents. The immunoassay of the invention comprises the steps of adding thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents, and measuring PIVKA-II in serum or plasma.Type: GrantFiled: June 1, 2000Date of Patent: May 17, 2005Assignee: Sanko Junyaku Co., Ltd.Inventors: Motohito Kanashima, Tomohide Asai, Hiroki Takahashi, Yoshiyuki Asai